Defensins
Alpha/beta defensins
Class of endogenous antimicrobial peptides. No FDA-approved drug product.
Glycopeptide antibiotic for gram-positive infections including MRSA.
Vancomycin (Vancocin) is a glycopeptide antibiotic in widespread clinical use for over 60 years. Vancomycin products are FDA-approved for serious gram-positive infections including MRSA bacteremia, endocarditis, and several other indications. Oral vancomycin is approved for C. difficile colitis and S. aureus enterocolitis.
Inhibits bacterial cell wall synthesis through binding to peptidoglycan precursors. Active against most gram-positive organisms including MRSA, though vancomycin-intermediate and vancomycin-resistant strains are increasingly encountered.
Vancomycin is appropriately prescribed by infectious disease, hospital medicine, primary care, or surgery depending on context. IV use requires hospital or infusion-center administration. Oral use for C. difficile is typically managed by gastroenterology, infectious disease, or primary care. Not appropriate for an outpatient clinic.
Infectious disease, hospital medicine, primary care, or gastroenterology depending on indication.
Alpha/beta defensins
Class of endogenous antimicrobial peptides. No FDA-approved drug product.
Cathelicidin
The only known human cathelicidin antimicrobial peptide. Not FDA-approved; investigational.